Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma

PHASE1CompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

August 31, 2011

Study Completion Date

August 31, 2011

Conditions
Brain and Central Nervous System Tumors
Interventions
BIOLOGICAL

therapeutic autologous lymphocytes

Cycles of escalating cell dose infusions up to the target cell dose of 10(8)

GENETIC

gene expression analysis

At the time of excess pathology samples documenting response/relapse

OTHER

laboratory biomarker analysis

CSF generated at the time of each T-cell dose

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

City of Hope Medical Center

OTHER

NCT00730613 - Cellular Adoptive Immunotherapy Using Genetically Modified T-Lymphocytes in Treating Patients With Recurrent or Refractory High-Grade Malignant Glioma | Biotech Hunter | Biotech Hunter